A randomized, double blind, double dummy, placebo controlled study to evaluate the efficacy and safety of solifenacin succinate (5 and 10mg once daily) against placebo and oxybutynin hydrochloride (5 mg three times daily) in the treatment of subjects with neurogenic detrusor overactivity.

Trial Profile

A randomized, double blind, double dummy, placebo controlled study to evaluate the efficacy and safety of solifenacin succinate (5 and 10mg once daily) against placebo and oxybutynin hydrochloride (5 mg three times daily) in the treatment of subjects with neurogenic detrusor overactivity.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Solifenacin (Primary) ; Oxybutynin
  • Indications Detrusor instability; Multiple sclerosis; Spinal cord disorders
  • Focus Therapeutic Use
  • Acronyms SONIC
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 28 Feb 2012 Interim results presented at the 27th Congress of the European Association of Urology.
    • 27 Oct 2011 Other source identified and integrated: ClinicalTrials.gov record NCT00629642.
    • 27 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top